Loading cancer entity…
Loading cancer entity…
Clinical trials
125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (24)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02223208 | Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas(FIL_PTCL13) | completed | Phase 1 / Phase 2 | 89 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05290155 | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies | completed | Phase 1 | 14 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER |
| 1 |
| Jun 6, 2025 |
| clinicaltrials |
| NCT02168140 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 | 16 | Wake Forest University Health SciencesOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT02561273 | Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 54 | University of NebraskaOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT01336920 | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | Phase 1 | 15 | University of NebraskaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT00644189 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT01075321 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 58 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | completed | Phase 1 | 58 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | May 31, 2019 | clinicaltrials |
| NCT01590732 | Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma | completed | Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT01658319 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT01198665 | RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas(RADCHOP) | completed | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00499811 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT00769288 | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2014 | clinicaltrials |
| NCT01129180 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | Phase 1 | 8 | Pierluigi PorcuOTHER | 1 | Dec 3, 2013 | clinicaltrials |
| NCT00293345 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00348985 | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00004241 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00089271 | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077155 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098891 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials